Differential gene expression activity among species-specific polypyrimidine/polypurine motifs in mu opioid receptor

Chung-Youl Choe1, Jinping Dong, Ping-Yee Law

  • 1Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. chungychoe@gmail.com

Gene
|October 16, 2010
PubMed

Insights

Species-specific structures of the mu opioid receptor (MOR) gene enhancer (PPy/u motif) impact its expression. Structural differences, not just sequence, dictate gene regulation and opioid analgesic function.

Area of Science:

  • Genetics
  • Molecular Biology
  • Pharmacology

Background:

  • The mu opioid receptor (MOR) is a key target for opioid analgesics.
  • Understanding MOR gene expression across species is crucial for human pain management.

Purpose of the Study:

  • To investigate the cross-species variations in the PPy/u motif, a critical enhancer of MOR gene expression.
  • To determine how structural differences in the PPy/u motif affect gene expression activity.

Main Methods:

  • Comparative analysis of PPy/u motifs from mouse, rat, and human.
  • Reporter gene assays to measure enhancer activity.
  • Circular dichroism, confocal Raman spectroscopy, S1 nuclease, and restriction enzyme assays to study DNA structure.
  • Topoisomerase II assays to assess torsional stress.

Main Results:

  • Mouse PPy/u motif shows high homology but significantly higher reporter gene activity than rat and human motifs.
  • Structural differences in PPy/u oligonucleotides, particularly in the phosphodiester backbone, were identified.
  • Conformational disparities lead to varied torsional stress and differential gene expression levels.

Conclusions:

  • Homologous PPy/u motifs exhibit unique, species-specific conformations that influence gene expression mechanisms and activity.
  • The structural conformation of transcription regulatory elements is a significant factor in functional gene expression, beyond mere sequence homology.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences.  The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...